加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01167 加科思-B

午间休市 09-08 12:05:00

6.040

-0.080

-1.31%

最高6.480	最低6.000	成交量80.04万
今开6.480	昨收6.120	日振幅7.84%
总市值47.23亿	流通市值47.23亿	总股本7.82亿
成交额484.22万	换手率0.10%	流通股本7.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01167","market":"HK","secType":"STK","nameCN":"加科思-B","latestPrice":6.04,"timestamp":1788840300002,"preClose":6.12,"halted":0,"volume":800400,"delay":0,"changeRate":-0.013071895424836612,"floatShares":782000000,"shares":782000000,"eps":-0.2202503996377693,"marketStatus":"午间休市","change":-0.08,"latestTime":"09-08 12:05:00","open":6.48,"high":6.48,"low":6,"amount":4842226,"amplitude":0.078431,"askPrice":6.06,"askSize":2700,"bidPrice":6.04,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":0.7750802750523355,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788843600000},"marketStatusCode":3,"adr":0,"listingDate":1608480000000,"exchange":"SEHK","adjPreClose":6.12,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.622038,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01167","defaultTab":"news","newsList":[{"id":"1181282043","title":"加科思-B 8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1181282043","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181282043?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:46","pubTimestamp":1788511613,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年9月4日披露了截至2026年8月31日的股份变动月报表。公告显示，公司于报告期内未发生新增发行、购回或注销股份等情况，股本维持稳定。报告期末已发行股份数为782,178,180股，库存股数为9,576,900股，已发行股份总数为791,755,080股。公司确认已符合香港联交所对于公众持股量的相关要求。该公告由公司董事王晓洁签署。公司表示，将继续严格遵守香港联交所《上市规则》及其他相关法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778277","title":"港股异动 | 加科思-B(01167.HK)再涨超11% 机构看好JAB-23E73为潜在的重磅资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662778277?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:54","pubTimestamp":1787810060,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200033","title":"港股异动 | 加科思-B(01167.HK)早盘涨超13% 上半年纯利超6亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200033","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200033?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:34","pubTimestamp":1787625242,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197407250","title":"内房股、医药股、加密货币现货 ETF 齐造好，中国奥园升 5%，加科思飙10%，嘉实比特币、博时比特币升 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197407250","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197407250?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:50","pubTimestamp":1787622642,"startTime":"0","endTime":"0","summary":"内房股、医药股、加密货币现货 ETF 齐造好，中国海外宏洋集团升 7%，中国奥园升 5%；加科思飙10%，云顶新耀升 5%；嘉实比特币、博时比特币升 3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c5f6cd84096ca9b3b893fb788b76d134","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c5f6cd84096ca9b3b893fb788b76d134"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","03883","03439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661527918","title":"加科思-B(01167)发布中期业绩，股东应占收益6.01亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661527918","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661527918?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:48","pubTimestamp":1787575700,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布截至2026年6月30日止6个月中期业绩，该集团取得收入7.31亿元，同比增加1500.5%;公司拥有人应占收益6.01亿元，去年同期则取得亏损5899.4万元;每股基本盈利0.78元。公告称，收入增长主要由于就 JAB-23E73的全球研发、生产及商业化与AstraZeneca AB进行的战略合作;及就艾瑞凯®及sitneprotafib的研发、生产及商业化与艾力斯订立的对外许可及服务协议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109332569","title":"加科思-B（01167）发布2026年中期业绩：营收7.31亿元 首录6.01亿元净利","url":"https://stock-news.laohu8.com/highlight/detail?id=1109332569","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109332569?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:46","pubTimestamp":1787575563,"startTime":"0","endTime":"0","summary":"8月24日，加科思-B披露截至2026年6月30日止六个月未经审计中期业绩。期内，受两项对外授权合作带动，集团收入由2025年同期的0.46亿元大增至7.31亿元，同比增幅1,499.3%。主要贡献来源为：与AstraZeneca AB就pan-KRAS抑制剂JAB-23E73的全球合作所确认的预付款及研发成本补偿，以及与上海艾力斯医药科技股份有限公司（艾力斯）就艾瑞凱及sitneprotafib授权及服务协议产生的收入。北京加科思与AstraZeneca AB于2025年12月达成合作，2026年3月已收取1亿美元预付款。董事会决定不派发2026年中期股息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121845025","title":"加科思-B(01167)拟于2026年8月24日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1121845025","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121845025?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:42","pubTimestamp":1786524168,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司（股票代码：01167）8月12日发布公告称，公司董事会已排期于2026年8月24日（星期一）召开会议。\n届时，董事会将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并处理其他事项。\n公告显示，董事会成员包括董事长兼执行董事王印祥博士；执行董事王晓洁女士、胡云雁女士；非执行董事陈德礼博士；以及独立非执行董事宋瑞霖博士、鲁白博士和吴革博士。\n该公告由董事会主席王印祥代表董事会签署并于2026年8月12日在香港发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658653179","title":"港股异动 | 加科思-B(01167.HK)盈喜后涨超6% 公司首次实现溢利 预期中期净溢利不少于6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658653179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658653179?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:33","pubTimestamp":1786412000,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658664935","title":"加科思-B(01167)发盈喜 预期中期净溢利不少于6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658664935","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658664935?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:56","pubTimestamp":1786363009,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B 发布公告，截至2026年6月30日止六个月预期公司将取得不少于人民币6亿元的净溢利，而截至2025年6月30日止六个月则取得净亏损约人民币5899万元。此乃公司首次实现溢利。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B(01167)发盈喜 预期中期净溢利不少于6亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186109965","title":"加科思-B发布正面盈利预告：预计上半年扭亏为盈录得不少于6亿元净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=1186109965","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186109965?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:56","pubTimestamp":1786362972,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司8月10日披露正面盈利预告称，根据截至2026年6月30日止六个月的未经审计综合管理账目及董事会现有资料的初步评估，预计报告期内将录得不少于6亿元的净溢利，而上年同期则录得净亏损约58.99百万元。这是公司首次实现盈利。公司强调，上述数据基于初步评估，尚未经核数师及董事会审核委员会审阅，最终业绩可能与当前披露数字存在差异。公司计划于2026年8月公布中期业绩报告。公司提醒股东及潜在投资者谨慎决策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192895415","title":"加科思-B预计2026年上半年净利润不低于6亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1192895415","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192895415?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:55","pubTimestamp":1786362910,"startTime":"0","endTime":"0","summary":"加科思-B（JACOBIO-B）发布业绩预告，预计截至2026年6月30日的六个月期间，公司净利润将不低于人民币6亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193793631","title":"加科思-B更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193793631","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193793631?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:51","pubTimestamp":1786006273,"startTime":"0","endTime":"0","summary":"2026年8月6日，加科思药业集团有限公司发布截至2026年7月31日的股份变动月报表，披露公司当月股本结构及股份变动情况。公司于2026年7月间在场内进行多次股份回购，共回购907,800股普通股，交易日期分别为2026年7月7日、8日、9日、13日、14日、17日、21日、23日及24日，回购价格区间为每股港币4.65元至5.08元。上述已回购股份暂以库存股形式持有，且截至本期末尚未注销。公司同时确认，已遵守香港联交所规定的最低公众持股量要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654606740","title":"加科思-B(01167.HK)：完成BET抑制剂JAB-8263用于类风湿关节炎的IIa期临床试验在中国的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2654606740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654606740?lang=zh_cn&edition=full","pubTime":"2026-07-27 06:53","pubTimestamp":1785106397,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132175725","title":"加科思-B（01167）BET抑制剂JAB-8263在华完成类风湿关节炎IIa期首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1132175725","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132175725?lang=zh_cn&edition=full","pubTime":"2026-07-27 06:46","pubTimestamp":1785105968,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司7月27日自愿公告，其自主研发的高活性BET抑制剂JAB-8263用于类风湿关节炎的IIa期临床试验已在中国完成首例患者给药。这是全球首个在RA领域开展临床试验的BET抑制剂项目，标志着该产品管线由肿瘤拓展至自身免疫疾病领域。加科思强调，JAB-8263拥有全球知识产权，作为口服小分子药物，预计可通过调节表观遗传状态改善患者长期治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164427729","title":"加科思-B：7月24日回购9.90万股，耗资约49.70万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164427729","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164427729?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:42","pubTimestamp":1784889734,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司(01167)于2026年7月24日公布翌日披露报表，显示公司当日通过香港联交所场内回购股份9.90万股，占彼时公司已发行股本约0.01266%。每股回购价介乎每股5.01港元至5.03港元，合计耗资约49.70万港元。\n回购完成后，公司已发行股本总数保持791,755,080股，其中包括流通股782,178,180股及库存股9,576,900股。根据2026年6月5日通过的回购授权，公司可回购股份上限为78,372,528股，其中已回购1,547,100股。\n公司在公告中确认已遵守相关上市规则和适用法律法规。公告由董事王晓洁签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B：7月24日回购9.90万股，耗资约49.70万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121939586","title":"加科思-B7月23日回购9.78万股，耗资约49.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121939586","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121939586?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:46","pubTimestamp":1784807216,"startTime":"0","endTime":"0","summary":"2026年7月23日，加科思药业集团有限公司发布翌日披露报表，公告当日在香港联交所场内进行股份回购。公告显示，公司于7月23日回购普通股9.78万股，约占本次回购前已发行股本的0.0125%，每股回购价介乎5.03港元至5.12港元，总耗资497,268港元。公司于2026年6月5日获得购回授权，授权可回购股份总数为78,372,528股。截至目前，基于该授权已回购1,448,100股，剩余可回购股份额度为76,924,428股。公告由董事王晓洁签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B7月23日回购9.78万股，耗资约49.73万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653429207","title":"加科思-B(01167)7月23日斥资49.7万港元回购9.78万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653429207","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653429207?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:37","pubTimestamp":1784806657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年7月23日斥资49.7万港元回购9.78万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135489982","title":"加科思-B7月21日回购9.84万股，涉资约49.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135489982","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135489982?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:02","pubTimestamp":1784635348,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月21日发布公告，披露当日进行了股份购回。公告显示，公司当日回购98,400股普通股，占回购前已发行股本约0.01258%。每股购回价格介乎港币5.06元至5.08元，合计涉资港币49.86万元。回购完成后，公司已发行股份数目为782,374,980股，库藏股数目为9,380,100股。购回授权于2026年6月5日获通过，公司可根据该授权购回股份总数为78,372,528股，已累计购回1,350,300股。本次公告由董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B7月21日回购9.84万股，涉资约49.86万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272527","title":"加科思-B(01167)7月21日斥资49.86万港元回购9.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272527","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653272527?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:52","pubTimestamp":1784634762,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年7月21日斥资49.86万港元回购9.84万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652267235","title":"港股异动 | 加科思-B(01167.HK)午后涨超8% JAB-23E73联合化疗试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652267235","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652267235?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:12","pubTimestamp":1784527961,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jacobiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0286},{"period":"1month","weight":0.2658},{"period":"3month","weight":0.4134},{"period":"6month","weight":-0.1368},{"period":"1year","weight":-0.4636},{"period":"ytd","weight":-0.0392}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"加科思药业集团有限公司是一家主要从事临床阶段新药研发的投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。该公司主要药物开发项目包括JAB-21822及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.0037},{"month":2,"riseRate":0.5,"avgChangeRate":0.158834},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.004688},{"month":4,"riseRate":0.666667,"avgChangeRate":0.034456},{"month":5,"riseRate":0.333333,"avgChangeRate":0.005017},{"month":6,"riseRate":0,"avgChangeRate":-0.071939},{"month":7,"riseRate":0.333333,"avgChangeRate":0.057712},{"month":8,"riseRate":0.333333,"avgChangeRate":0.062961},{"month":9,"riseRate":0.5,"avgChangeRate":-0.006627},{"month":10,"riseRate":0.2,"avgChangeRate":-0.065405},{"month":11,"riseRate":0.4,"avgChangeRate":0.020921},{"month":12,"riseRate":0.2,"avgChangeRate":-0.06824}],"exchange":"SEHK","name":"加科思-B","nameEN":"JACOBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"加科思-B,01167,加科思-B股票,加科思-B股票老虎,加科思-B股票老虎国际,加科思-B行情,加科思-B股票行情,加科思-B股价,加科思-B股市,加科思-B股票价格,加科思-B股票交易,加科思-B股票购买,加科思-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}